Left to right: Emmanuel Petit (Football player, BrainEye Brand Ambassador), Associate Professor Joanne Fielding (Chief Scientific Officer, BrainEye), Lauren Adams (Australia’s Trade and Investment Commissioner), and Steven Barrett (COO, BrainEye)
BrainEye, an Australian health-tech company, is preparing to introduce its AI-driven brain health screening app to the Indonesian market. This will mark a significant milestone in its mission to make neurological health assessments more accessible and affordable.
With a growing global focus on brain health and concussion safety, BrainEye offers a smartphone-based platform that delivers rapid, non-invasive assessments of brain function. Using artificial intelligence (AI) and machine learning, the app provides a snapshot of a user’s neurological health in under 40 seconds without the need for expensive hardware or clinical environments.
Steven Barrett, Chief Operating Officer at BrainEye, in an email interview with e27, highlighted the scale of the issue the company seeks to address. “Neurological disorders are the leading cause of disability worldwide. It is estimated that one in three people will suffer from a neurological disorder at some point in their lifetime. Yet, as many as 75 per cent of those affected go undiagnosed until symptoms are disabling … Our aim is to reduce this gap by providing an early indicator of dysfunction.”
BrainEye’s upcoming Indonesian launch is supported by French football legend Emmanuel Petit, a FIFA World Cup and UEFA European Champion. As BrainEye’s brand ambassador, Petit advocates for greater awareness of brain health and concussion safety in sports, particularly in grassroots and community settings where access to medical professionals may be limited.
In sports, BrainEye’s tech is poised to address longstanding concerns about the effectiveness of traditional concussion protocols. The company argues that conventional methods, such as the Sports Concussion Assessment Tool (SCAT), rely heavily on subjective observation and are typically deployed after symptoms manifest.
Also Read: The neuroscience of startups: Unlocking the brain’s potential for business success
By contrast, BrainEye offers objective, real-time data that has proven up to three times more reproducible than SCAT.
“In clinical trials with elite AFL athletes, BrainEye achieved 100 per cent sensitivity and 85 per cent specificity, successfully identifying players diagnosed with concussion through abnormal eye movement data,” Barrett shared.
“This empowers club doctors with real-time insights and extends vital concussion screening to schools, academies and community sports clubs, where 95 per cent of athletes do not have immediate access to medical professionals.”
At the core of BrainEye’s solution is the digitisation of ocular motility tests, which have long been used by frontline medical personnel to assess neurological function.
“Eye movements are generally very stereotyped, so any change in brain function will manifest through a change in ocular motility,” Barrett explained. “We have digitised this process, making it more objective and sensitive to subtle changes that might otherwise go unnoticed.”
The tech has been clinically measured and validated against gold-standard clinical devices, distinguishing it from many competitors in the market. With over 120,000 tests performed worldwide, BrainEye is classified as a Class 1M medical device and is designed for use across various sectors, including clinical neurology, sports safety, mental wellness, and elder care.
Machine learning plays a pivotal role in BrainEye’s precision and reliability.
“The more data we collect, the more accurate our app becomes,” Barrett noted. “Our algorithms are constantly tightening, becoming more accurate and reliable with every test. AI is central to our current success and future evolution as a leader in brain health technology.”
Also Read: Neuroscience-backed productivity tips every tech founder should adopt
The app allows users to monitor their brain health over time, with consistent downward trends prompting medical consultation. Early identification of potential neurological issues opens the door to earlier intervention and better patient outcomes.
“Earlier identification means earlier treatment, leading to better patient outcomes and reduced healthcare costs,” Barrett said. “For caregivers, disease progression can be slowed, reducing the intensity of care needed. Meanwhile, healthcare systems benefit from reduced physical and economic burdens as conditions are more effectively managed.”
Barrett acknowledged the challenges involved in developing the platform, particularly in securing data from unhealthy populations and balancing user-friendliness with data accuracy. “Usability was a major focus. The app is user-friendly, but it requires users to keep their hands and heads still during testing. Striking that balance was not easy,” he noted.
The team has also placed significant emphasis on ensuring regulatory compliance. BrainEye’s certified quality management system is built on established software development and risk management standards, with data encryption and high-level security protocols in place.
The company has secured approval from Australia’s Therapeutic Goods Administration (TGA), a milestone that paves the way for further approvals in other jurisdictions, including Southeast Asia.
“AI regulation is at the forefront of every major jurisdiction,” Barrett said. “Securing regulatory approval for our cutting-edge technology has been one of our biggest challenges, but it also underscores the robustness of our approach.”
As BrainEye prepares for its Indonesian rollout, the company remains focused on expanding both its platform capabilities and its global footprint. “We are presented with new use cases every time we meet someone new. There is so much potential,” Barrett added.
—
Image Credit: BrainEye
The post AI-powered brain health app BrainEye sets sights on Indonesia launch appeared first on e27.